Advanced Colorectal Cancer with Marwan G. Fakih, MD Case 2

Video

Advanced Colorectal Cancer with Marwan G. Fakih, MD

Case Scenario 2:

  • A 57-year old man presented for routine colonoscopy and was found to have a descending colon moderately differentiated adenocarcinoma. CEA pre-operatively was 6.
  • Laparoscopic colectomy with colo-colonic anastomosis was performed. Final pathology showed a T3N2a (stage IIIb) lesion with 5/20 LNs positive. There was lymphovascular but no perineural invasion.
  • Mutation testing revealed a KRAS mutation. The tumor was MSS.
  • His ECOG performance status was 0.
  • Following surgery, he was given adjuvant therapy with FOLFOX for 12 cycles with oxaliplatin help during the last two cycles because of grade 2 neuropathy.
  • Six months later, follow-up imaging revealed recurrence and multiple metastatic hepatic lesions.
  • The patient was started on FOLFIRI plus bevacizumab.
Recent Videos
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Solly Chedid, MD, an expert on MDS
Related Content
Invikafusp Alfa Shows Potential in PD-1 Refractory Solid Tumors

Invikafusp Alfa Shows Potential in PD-1 Refractory Solid Tumors

Jordyn Sava
November 21st 2024
Article

Invikafusp alfa showed promise as a treatment option across a range of high tumor mutational burden cancers or virally associated malignancies.

Read More

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Jordyn Sava;Arvind Dasari, MD, MS
November 15th 2023
Podcast

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

Listen

FDA Approves Cologuard Plus Stool DNA Test for Colorectal Cancer Screening

FDA Approves Cologuard Plus Stool DNA Test for Colorectal Cancer Screening

Sabrina Serani
October 4th 2024
Article

The noninvasive test provides a beneficial screening tool for patients 45 and older at average risk for colorectal cancer.

Read More

Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers

Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers

Michael J. Overman, MD;Nichole Tucker
July 15th 2021
Podcast

In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer

Listen

No Survival Advantage Seen With Ramucirumab and TAS-102 in Metastatic Colorectal Cancer

No Survival Advantage Seen With Ramucirumab and TAS-102 in Metastatic Colorectal Cancer

Caroline Seymour
September 15th 2024
Article

The combination of ramucirumab with trifluridine/tipiracil failed to show improvements in overall survival vs TAS-102 alone in heavily pretreated metastatic colorectal cancer.

Read More

Phase 3 Trials of Botensilimab/Balstilimab Move Forward, Despite FDA's Approval Setback

Phase 3 Trials of Botensilimab/Balstilimab Move Forward, Despite FDA's Approval Setback

Jordyn Sava
July 18th 2024
Article

Agenus was advised by the FDA against filing for accelerated approval of botensilimab plus balstilimab for relapsed/refractory microsatellite stable metastatic colorectal cancer without liver metastases.

Read More